Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

 
• By Sarah Karlin-Smith
  
sign that reads "false"
Promoting clinical benefits of an interchangeable over standard biosimilars is likely to be considered false and misleading by the FDA • Source: Shutterstock

More from Biosimilars

More from Products